Immunicum’s vaccine is based on using dendritic cells from healthy individuals and can be mass-produced, leading to commercial advantages, the company said.
The study will be conducted on kidney cancer patients at the University Hospital in Uppsala.
A clinical phase I/II trial will begin on twelve patients with metastatic renal cancer, which would evaluate the safety and efficacy of the vaccine.